Full-Time

Talent Acquisition Partner

Posted on 4/10/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Mid, Senior

No H1B Sponsorship

Mississauga, ON, Canada

The job requires in-office work 3 days a week, indicating a hybrid work model.

Category
Technical Recruiting
People & HR
Requirements
  • Demonstrable experience in Talent Acquisition – within a regional and global environment
  • Experience in delivering full life cycle recruitment services in an in-house environment or agency environment
  • Experience of planning and leading complex recruitment campaigns for hard to fill skills sets using a range of methods and tools attraction channels
  • Experience with Workday application tracking system or other related system
  • Ability to adopt and utilise digital/AI tools
  • Stakeholder management and relationship building skills
  • Ability to work in a fast-paced changing agile environment
  • Customer focused, results orientated approach
  • Persuading and influencing skills, with a strong ability to manage expectations
  • Written and spoken proficiency in English
Responsibilities
  • Deliver Talent Acquisition solutions seamlessly – aligned to a business area/capability in partnership with the Hiring Manager, HR Business Partner and Talent Acquisition colleagues
  • Proactively identify and fill vacancies with talented individuals with the right capabilities and skills in a fast-paced challenging market
  • Manage the entire recruitment process, from initial candidate contact to offer, ensuring a smooth and positive candidate experience
  • Ensure that all recruitment activities are compliant with our policies and procedures
Desired Qualifications
  • Educated to degree level/postgraduate qualification in a HR related specialism
  • Minimum of 4 years recruiting experience in the pharmaceutical industry preferred (Recruiting sales and commercial roles)
  • Experience in oncology recruitment is highly valued
  • Proficiency in both English and French is highly valued

AstraZeneca develops and sells prescription medicines, focusing on three main areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are created through extensive research and development, which includes clinical trials and regulatory approvals. Unlike competitors, AstraZeneca emphasizes collaboration through its Open Innovation program and the A.Catalyst Network, connecting health innovation hubs worldwide. The company's goal is to advance healthcare by providing effective treatments for serious diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency and innovation.
  • Real-world evidence supports AstraZeneca's drug efficacy and safety demonstrations.
  • Personalized medicine aligns with AstraZeneca's focus on precision therapies.

What critics are saying

  • Class-action lawsuit over Soliris could lead to legal costs and reputational damage.
  • AI tool for breast cancer screening may face challenges in minority representation.
  • Foreign investment regulations in France may impact AstraZeneca's Dunkirk expansion.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapeutic areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery by sharing compounds and technologies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
Apr 22nd, 2025
Enhertu Combination Improved Pfs In 1L Her2+ Mbc

Enhertu combination improved PFS in 1L HER2+ mBC

Life Sciences IP Review
Apr 17th, 2025
AstraZeneca unit faces class-action suit over alleged Soliris monopoly

AstraZeneca unit faces class-action suit over alleged soliris monopoly.

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

INACTIVE